Synexus continues expansion across Eastern Europe with three new clinical trial centres
Adds new centres in Bulgaria, Poland and Romania
Synexus, a multi-national company focused on the recruitment for and running of clinical trials, continues to expand across Eastern Europe with three new research centres in Bulgaria, Poland and Romania, bringing the total to nine in Eastern Europe. The UK-based company now has a total of 25 research centres across Europe and Africa providing pharmaceutical clients and contract research organisations with an expanding pool of patients.
The new Polish facility, Synexus' largest globally, occupies 1,000m2 on Beniowskiego Street in Gdansk.
Christophe Berthoux, CEO at Synexus, said: 'This is our ninth Dedicated Research Centre in Eastern Europe which will help us to provide much greater support to the global pharmaceutical industry. Since we opened our first centre in Poland in 2006 we have had an ongoing programme of investment in the region. Throughout the world we are upgrading our centres to provide the very latest facilities for our patients and to provide our clients in pharma with the most accurate data.'
Romania’s new 820m2 centre is based in Bucharest, which has a population of two million. Romania has been part of Synexus’ development plans since early 2000, as the country’s total population is more than 20 million and the number of new clinical trials granted approval during the last five years is at least 200.
The centre in Sofia, Bulgaria, occupies 650m2 and includes eight medical rooms, two administration rooms, monitoring and meeting rooms and other areas. This centre will offer patients access to new drugs in the fields of pulmonology, rheumatology, neurology, endochrinology, cardiology, gastroenterology and dermatology.
All 25 Synexus clinics across Europe and Africa focus on undertaking clinical trials in the therapy areas where the company can provide most value. Particular attention is devoted to the areas of cardiovascular, metabolic (diabetes and obesity), musculoskeletal, respiratory and central nervous system (dementia and pain) trials.